Literature DB >> 22285529

Allele-selective inhibition of trinucleotide repeat genes.

Masayuki Matsui1, David R Corey.   

Abstract

Expanded trinucleotide repeats cause Huntington's disease (HD) and many other neurodegenerative disorders. There are no cures for these devastating illnesses and treatments are urgently needed. Each trinucleotide repeat disorder is the result of the mutation of just one gene, and agents that block expression of the mutant gene offer a promising option for treatment. Therapies that block expression of both mutant and wild-type alleles can have adverse effects, challenging researchers to develop strategies to lower levels of mutant protein while leaving adequate wild-type protein levels. Here, we review approaches that use synthetic nucleic acids to inhibit expression of trinucleotide repeat genes.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22285529      PMCID: PMC3468950          DOI: 10.1016/j.drudis.2012.01.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  59 in total

1.  Allele-specific silencing of dominant disease genes.

Authors:  Victor M Miller; Haibin Xia; Ginger L Marrs; Cynthia M Gouvion; Gloria Lee; Beverly L Davidson; Henry L Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2003-06-02       Impact factor: 11.205

2.  RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model.

Authors:  Scott Q Harper; Patrick D Staber; Xiaohua He; Steven L Eliason; Inês H Martins; Qinwen Mao; Linda Yang; Robert M Kotin; Henry L Paulson; Beverly L Davidson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-05       Impact factor: 11.205

3.  Antisense oligonucleotide therapy for neurodegenerative disease.

Authors:  Richard A Smith; Timothy M Miller; Koji Yamanaka; Brett P Monia; Thomas P Condon; Gene Hung; Christian S Lobsiger; Chris M Ward; Melissa McAlonis-Downes; Hongbing Wei; Ed V Wancewicz; C Frank Bennett; Don W Cleveland
Journal:  J Clin Invest       Date:  2006-07-27       Impact factor: 14.808

4.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

Authors: 
Journal:  Cell       Date:  1993-03-26       Impact factor: 41.582

5.  Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion.

Authors:  J K White; W Auerbach; M P Duyao; J P Vonsattel; J F Gusella; A L Joyner; M E MacDonald
Journal:  Nat Genet       Date:  1997-12       Impact factor: 38.330

6.  Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue.

Authors:  S Zeitlin; J P Liu; D L Chapman; V E Papaioannou; A Efstratiadis
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

7.  Sequence-dependent and independent inhibition specific for mutant ataxin-3 by small interfering RNA.

Authors:  Yi Li; Takanori Yokota; Ryusuke Matsumura; Kazunari Taira; Hidehiro Mizusawa
Journal:  Ann Neurol       Date:  2004-07       Impact factor: 10.422

8.  Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders.

Authors:  Ivelisse Sánchez; Christian Mahlke; Junying Yuan
Journal:  Nature       Date:  2003-01-23       Impact factor: 49.962

9.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes.

Authors:  J Nasir; S B Floresco; J R O'Kusky; V M Diewert; J M Richman; J Zeisler; A Borowski; J D Marth; A G Phillips; M R Hayden
Journal:  Cell       Date:  1995-06-02       Impact factor: 41.582

10.  Inactivation of the Huntington's disease gene (Hdh) impairs anterior streak formation and early patterning of the mouse embryo.

Authors:  Juliana M Woda; Teresa Calzonetti; Paige Hilditch-Maguire; Mabel P Duyao; Ronald A Conlon; Marcy E MacDonald
Journal:  BMC Dev Biol       Date:  2005-08-18       Impact factor: 1.978

View more
  20 in total

1.  Digital quantitation of potential therapeutic target RNAs.

Authors:  David W Dodd; Keith T Gagnon; David R Corey
Journal:  Nucleic Acid Ther       Date:  2013-05-08       Impact factor: 5.486

Review 2.  Expanded complexity of unstable repeat diseases.

Authors:  Urszula Polak; Elizabeth McIvor; Sharon Y R Dent; Robert D Wells; Marek Napierala
Journal:  Biofactors       Date:  2012-12-11       Impact factor: 6.113

3.  Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.

Authors:  Dongbo Yu; Hannah Pendergraff; Jing Liu; Holly B Kordasiewicz; Don W Cleveland; Eric E Swayze; Walt F Lima; Stanley T Crooke; Thazha P Prakash; David R Corey
Journal:  Cell       Date:  2012-08-31       Impact factor: 41.582

Review 4.  Cell-based therapies for Huntington's disease.

Authors:  Yiju Chen; Richard L Carter; In K Cho; Anthony W S Chan
Journal:  Drug Discov Today       Date:  2014-03-12       Impact factor: 7.851

5.  Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice.

Authors:  Mireia Garriga-Canut; Carmen Agustín-Pavón; Frank Herrmann; Aurora Sánchez; Mara Dierssen; Cristina Fillat; Mark Isalan
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-10       Impact factor: 11.205

6.  Limits of using oligonucleotides for allele-selective inhibition at trinucleotide repeat sequences - targeting the CAG repeat within ataxin-1.

Authors:  Jiaxin Hu; David R Corey
Journal:  Nucleosides Nucleotides Nucleic Acids       Date:  2019-10-24       Impact factor: 1.381

7.  Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease.

Authors:  Lisa M Stanek; Sergio P Sardi; Bryan Mastis; Amy R Richards; Christopher M Treleaven; Tatyana Taksir; Kuma Misra; Seng H Cheng; Lamya S Shihabuddin
Journal:  Hum Gene Ther       Date:  2014-03-21       Impact factor: 5.695

8.  Phosphorodiamidate morpholino oligomers suppress mutant huntingtin expression and attenuate neurotoxicity.

Authors:  Xin Sun; Leonard O Marque; Zachary Cordner; Jennifer L Pruitt; Manik Bhat; Pan P Li; Geetha Kannan; Ellen E Ladenheim; Timothy H Moran; Russell L Margolis; Dobrila D Rudnicki
Journal:  Hum Mol Genet       Date:  2014-07-04       Impact factor: 6.150

9.  Allele-selective inhibition of expression of huntingtin and ataxin-3 by RNA duplexes containing unlocked nucleic acid substitutions.

Authors:  Yuichiro Aiba; Jiaxin Hu; Jing Liu; Qin Xiang; Carlos Martinez; David R Corey
Journal:  Biochemistry       Date:  2013-11-27       Impact factor: 3.162

10.  Synthesis and characterization of oligodeoxyribonucleotides modified with 2'-amino-α-L-LNA adenine monomers: high-affinity targeting of single-stranded DNA.

Authors:  Nicolai K Andersen; Brooke A Anderson; Jesper Wengel; Patrick J Hrdlicka
Journal:  J Org Chem       Date:  2013-12-11       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.